Halberd

What Halberd does

Halberd Corporation is a publicly traded, Jackson Center, Pennsylvania-based micro-cap company (OTC PINK: HALB) that develops therapeutics and diagnostics targeting neurological injury, with an emphasis on traumatic brain injury (TBI), PTSD, and related neurodegenerative and behavioral conditions. Its product portfolio spans multiple modalities: Tri-aX, a nasal spray formulation intended to mitigate TBI damage; LDN+, a drug combination therapy; the Sequential Dialysis Technique for removing neurotoxic substances; Vita-Shield-Max, a nutraceutical; and WatchDawg, a wearable monitoring device for PTSD-affected patients. The portfolio is protected by 4 issued patents (including US 9,216,386 and US 8,758,287) and 22 pending applications, and is supported by research collaborations with Mississippi State University, Youngstown State University, and Arizona State University.

Halberd's commercial model is channel-mediated rather than direct. The company accesses federal procurement through revenue-sharing partnerships with Athena GTX (covering WatchDawg, Vita-Shield-Max, and the Sequential Dialysis Technique) and Defense Atomics Corporation, and accesses civilian hospital and pharmacy channels through a worldwide distribution agreement with CrodenHealth (December 2023). Veteran outreach is supported through the Exalted Warrior Foundation and Hamden Group. Pricing is not publicly disclosed, and no revenue figures are reported.

In September 2025, Halberd acquired NeuroSense AI Corp, adding a voice-based behavioral intelligence platform that fuses voice, movement, and social interaction data via a four-step pipeline (Capture, Analyze, Interpret, Track) integrated with Anthropic's Claude AI. The platform is positioned for real-time stress and behavioral tracking in military, veteran, athlete, and civilian populations, with a stated roadmap to incorporate EEG and biomarker streams. Headcount stands at 1-10 employees, and Halberd remains pre-commercial or sub-$1M revenue, with multiple core assets still pre-FDA or in research stages.

Name

Halberd

Legal name

Halberd Corporation

Website

https://halberdcorporation.com

Company type

Public

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Halberd (OTC PINK: HALB) is a Jackson Center, PA micro-cap developing therapeutics, wearables, and the NeuroSense AI behavioral intelligence platform for TBI, PTSD, and neurological injury, serving U.S. military, veteran, and civilian healthcare markets via channel partners.

Ownership category

akta.pro rank

Product category

Medical Therapeutics Development

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Electromedical & Electrotherapeutic Apparatus (3845), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)

akta.pro secondary industries

SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF), Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH)

Keywords

• Medical treatments research
• Extracorporeal blood therapy
• Behavioral intelligence platform
• Traumatic brain injury therapeutics
• Pharmaceutical drug development

Headquarters

HQ city

Jackson Center

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Operations, Marketing or Sales, Personnel, Others

Revenue model

1. Government Contracts: Pursuing government contracts for TBI treatment, PTSD solutions, and military health applications through Athena GTX partnership. Non-dilutive funding from government sources for research and clinical trials.
2. Pharmaceutical Product Sales: Worldwide distribution and sales of patented low dose naltrexone products through CrodenHealth and The Hamden Group partnerships.
3. Revenue Sharing: Revenue-sharing arrangements with Athena GTX from government contract proceeds. Non-dilutive financing where partners fund development in exchange for participation in success.
4. Technology Licensing: Licensing of proprietary technologies including extracorporeal treatment patents, laser eradication methodology, and behavioral intelligence platforms.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

Halberd Corporation develops and commercializes patented medical treatments and behavioral intelligence technologies targeting traumatic brain injury (TBI), PTSD, cancer, antibiotic-resistant infections, and other debilitating diseases. Its portfolio includes the NeuroSense AI voice-based behavioral monitoring platform, the LDN+ patented drug formulation, the Tri-aX TBI nasal spray, the WatchDawg wearable PTSD treatment/monitoring system, the Sequential Dialysis extracorporeal treatment technique, and the Vita-Shield-Max nutraceutical. The company monetizes primarily via government contracts, exclusive worldwide pharmaceutical distribution partnerships, and patent licensing.\n

Product overview

Halberd Corporation operates as a technology holding company focused on healthcare and medical applications with a portfolio of distinct products and platforms. The core offerings include NeuroSense AI, a voice-based behavioral intelligence platform (acquired and further developed by Halberd), which feeds into the WatchDawg® PTSD treatment system combining pharmaceuticals with continuous monitoring. Supporting the portfolio are Tri-aX™ Nasal Spray for TBI treatment, LDN+ patented pharmaceutical for addiction and mental health conditions, and the Sequential Dialysis Technique for extracorporeal disease treatment. Additional products include the Vita-Shield-Max™ nutraceutical. The company develops these through partnerships with research institutions including Mississippi State University, Youngstown State University, and Athena GTX for government contract support.

Differentiator

Problem solved

Functional benefit

Brands

• NeuroSense AI: Behavioral intelligence platform using multi-modal behavioral signal fusion powered by AI to analyze neurological changes, integrating vocal patterns, movement, and social interactions for TBI research and clinical assessment.
• WatchDawg

Products and services

• NeuroSense AI Voice-based behavioral intelligence platform that converts brief voice samples into repeatable, long-term health metrics for research and clinical care teams. Features a four-step pipeline (Capture, Analyze, Interpret, Track) integrating with Claude AI for pattern recognition, providing AI-assisted summaries, real-time stress scoring, longitudinal per-subject tracking, and seven-day baseline history. Designed for desktop-to-wearable integration under the WatchDawg product roadmap.\n
• WatchDawg PTSD treatment system combining pharmaceuticals (LDN+) and nutraceuticals with a 24/7 wearable physiological and psychological monitoring wrist monitor and mobile phone application enabled by the Athena GTX health monitoring system. Provides continuous monitoring via cloud-based data systems for research and clinical care teams serving military veterans.\n
• Tri-aX TBI Nasal Spray Patent-pending multi-part nasal spray treatment for traumatic brain injury that mitigates the cascade of inflammatory cytokines and neurotransmitters following head trauma. Demonstrated 52.3% reduction in GFAP biomarkers and 25% reduction in NSE biomarkers in Phase I animal testing. Targeted for early-intervention use by military personnel, contact-sport athletes, and emergency medical settings.\n
• LDN+ Pharmaceutical Patented combination of low-dose Naltrexone and Cyclobenzaprine indicated for treatment of PTSD, suicidal ideation, pain, anxiety, and chemical/alcohol addiction. Acts as antagonist against addiction while relieving pain and anxiety, distributed worldwide via CrodenHealth and The Hamden Group under exclusive licensing agreements.\n
• Sequential Dialysis Technique Proprietary extracorporeal methodology that physically removes the pathophysiologic basis of disease by applying treatment to bodily fluids (blood, cerebrospinal fluid, lymph) and substantially removing the treatment before returning fluid to the patient. Covered by U.S. Patent 9,216,386. Provides subtractive therapy as opposed to conventional additive pharmacological approaches, reducing side effects. Targets Covid-19 and other viruses, with future applications in Alzheimer's, PTSD/TBI, and cancer.\n
• Vita-Shield-Max Immune support nutraceutical product offered by Halberd Corporation and distributed worldwide via The Hamden Group alongside LDN+ medication.\n

Quantifiable outcome

• 52.3% reduction in Glial Fibrillary Acidic Protein (GFAP) levels in Phase I animal testing of TBI nasal spray
• +3 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability7 records

Feature7 records

Partnerships

Nine partnerships are on record, tiered major, core and supporting.

• Defense Atomics CorporationmajorStrategic or Co-development Partner · 11 September 2024Contract award commitment to fund key advanced research including FDA IND study using Halberd's LDX technology and WatchDawg system for PTSD and TBI treatment.
• Exalted Warrior FoundationcoreStrategic or Co-development Partner · 4 April 2024CRADA partnership for military PTSD clinical trials. 501(c)(3) nonprofit serving wounded warriors. Provides 24/7 mental health therapies integrated with LDN+ drug treatment and WatchDawg monitoring.
• Athena Telemedicine Partners, LLCmajorStrategic or Co-development Partner · 4 April 2024Partnership for clinical studies including 100-patient kidney disease study and WatchDawg PTSD pilot study with wearable monitoring.
• Athena GTX, Inc.coreStrategic or Co-development Partner · 9 January 2024Revenue-sharing agreement for government contracts. Athena GTX has 20+ years experience securing $4-5M annually in government R&D contracts. Assisting with DoD procurement and FDA certification for TBI nasal spray and LDN+ products.
• CrodenHealth.comcoreChannel Partner/ Reseller/ Distributor · 13 December 2023Worldwide agreement to produce, market, sell and distribute patented low dose naltrexone combo products. Right of first refusal on future products. Led by Peter Croden, former President of Upjohn/Pfizer Canada.
• Mississippi State University (MSU)coreStrategic or Co-development Partner · 15 November 2023Extended two-year research partnership for TBI nasal spray testing. Dr. Russell Carr serves as Principal Investigator. Phase I demonstrated 50%+ biomarker reduction. Phase II expanded testing approved by Institutional Animal Care and Use Committee.
• Youngstown State University (YSU)coreStrategic or Co-development Partner · 1 January 2023Research partner for laser eradication methodology and antibody/antigen experimentation. Dr. William G. Sturrus leads physics and laser application research. Successfully eradicated CDC-supplied antibiotic-resistant bacteria.
• The Hamden GroupmajorChannel Partner/ Reseller/ Distributor · 14 November 2022Worldwide exclusive rights to sell, market and distribute patented low-dose Naltrexone medication and Vita-Shield-Max nutraceutical products. Led by Croden family with 40+ years pharmaceutical experience.
• Arizona State University (ASU)supportingStrategic or Co-development Partner · 1 January 2020Research partner for initial development of extracorporeal treatment technology and antibody conjugation with metallic nanoparticles.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Altoida: Digital biomarker company using multi-modal smartphone/wearable data plus AI for neurological disease detection (including TBI and Alzheimer's); overlaps NeuroSense AI's voice/movement/behavioral fusion approach.
• Aptinyx: CNS-focused clinical-stage biotech developing novel NMDA-receptor-targeted therapeutics for pain, PTSD, and TBI; comparable to Halberd's LDN+ PTSD therapeutic strategy.

Direct peers

• Pear Therapeutics (now bankruptcy estate): Pioneer in FDA-authorized prescription digital therapeutics for CNS conditions including substance use disorder and PTSD; stands as the most direct historical precedent for Halberd's digital therapeutic pipeline.
• Tonix Pharmaceuticals: Public CNS-focused biotech developing therapeutics for TBI, PTSD, and related conditions; directly comparable to Halberd's LDN+ and TBI nasal spray programs targeting the same veteran and trauma indications.
• Cambridge Cognition: Public digital health company building computerized cognitive assessments and digital biomarkers for CNS research, trials, and clinical use; comparable to NeuroSense AI's longitudinal behavioral analytics offering.
• BrainScope Company: Commercial-stage TBI diagnostic and assessment technology company with military and DoD relationships; competes in the same traumatic brain injury evaluation/adjudication workflow Halberd is targeting with Tri-aX and NeuroSense AI.
• Akili Interactive: Digital therapeutics company that pioneered FDA-cleared software-as-a-medical-device products for cognitive conditions; directly comparable to Halberd's NeuroSense AI digital biomarker/behavioral platform strategy.

Broad incumbents

• Cogstate: Established commercial cognitive testing and digital endpoint company serving CNS clinical trials including TBI; addresses a similar research/clinical buyer base as Halberd's behavioral intelligence tools.

Others

• Mindstrong Health (acquired by Aptinyx-affiliate / Sonde): Behavioral biomarker analytics platform using smartphone-collected voice, tap, and movement signals for mental health monitoring; a direct conceptual analog to NeuroSense AI's multi-modal approach.

Regional players

• Lumos Pharma: Small US clinical-stage pharma developing neurological/rare disease therapies; similar size, stage, and capital profile to Halberd and indicative of comparable early-stage investor audience.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/halberdc
• Facebookfacebook.com/halberdc

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Halberd